GLP-1 Peptides: Pain, Gut, and Heart
New research on GLP-1 peptides links these therapies to pain relief, gut health, and cardiovascular benefits beyond weight loss. Here's what studies found.
Section
Industry
The companies and markets shaping the peptide field.
Looking for background? Browse the peptide research library — cited overviews of every compound, sorted by evidence tier.
-
-
Next-Gen Incretin Drugs: What Research Shows
New studies on incretin peptides reveal triple-hormone agonists, real-world weight loss gaps, and the post-cessation rebound challenge. Here's what the science shows.
-
GLP-1 Peptides: New Frontiers in 2025
GLP-1 peptides are reshaping medicine in 2025. New studies link them to addiction, clotting risk, genetics, and shifting surgical trends.
-
Incretin Peptides: Beyond Blood Sugar
New research on incretin peptides reveals links to addiction, clotting risk, allergic reactions, and surgical trends. Here's what the studies found.
-
GLP-1 Safety: What New Research Reveals
A wave of 2026 studies examines GLP-1 safety across older adults, kidney disease, heart failure, and micronutrient gaps. Here is what the evidence shows.
-
The Direct-to-Consumer Price War
With compounding curbed, Lilly and Novo now compete on cash prices for Zepbound and Wegovy via LillyDirect and NovoCare. How the price war works.
-
Building the Factory at Home
Eli Lilly pledged $27B and Novo Nordisk $10B to expand US GLP-1 manufacturing. Why onshoring, tariffs, and capacity are reshaping the obesity supply chain.
-
Novo Nordisk's Year of Reset
Novo Nordisk cut its outlook, lost Metsera to Pfizer, and saw an Alzheimer's trial fail. Inside the reset — and the amycretin bet on recovery.
-
Pfizer Wins Metsera — and a Platform
Pfizer beat Novo Nordisk to acquire Metsera for up to $10 billion, gaining a monthly-dosing obesity platform. How the bidding war unfolded and why it matters.
-
The Price of a Blockbuster, Renegotiated
A November 2025 White House deal cut GLP-1 prices to $245/month, opened Medicare to obesity drugs, and launched TrumpRx. Here's what changed and when.
-
A Peptide Company Just Set the Record for the Largest Venture-Backed Biotech IPO
Parabilis Medicines' Nasdaq debut, priced at a $670 million offering and closing at $770.5 million, puts a stabilized-peptide platform atop a ranking long ruled by antibody and small-molecule firms.
Frequently Asked Questions
What is Peptide News Network and what kind of content does it cover?
Peptide News Network is a science and medicine publication that covers peptide science, regulation, and industry news. According to its own description, it focuses on translating peer-reviewed science for a general audience, and every story cites its primary sources. Its Industry section specifically covers the companies and markets shaping the peptide field.
What significant financial milestone did a peptide company recently achieve, according to Peptide News Network?
According to Peptide News Network's June 11, 2026 report, Parabilis Medicines made its Nasdaq debut in what was described as the largest venture-backed biotech IPO on record for a peptide company. The offering was priced at $670 million and closed at $770.5 million.
What type of technology platform does Parabilis Medicines focus on?
Based on Peptide News Network's reporting, Parabilis Medicines is built around a stabilized-peptide platform. The publication noted that this IPO puts a stabilized-peptide platform atop a ranking that has historically been dominated by antibody and small-molecule firms.
How does Parabilis Medicines' IPO compare historically within the broader biotech industry?
According to Peptide News Network, Parabilis Medicines' Nasdaq debut set the record for the largest venture-backed biotech IPO, a ranking that had long been held by companies in the antibody and small-molecule sectors rather than the peptide field. This signals a notable shift in investor attention toward peptide-based medicines.
Does Peptide News Network provide medical advice to readers?
No. Peptide News Network explicitly states that nothing published on the site constitutes medical advice, and it directs readers to consult a licensed clinician before making any health decisions. This publication focuses on reporting science, regulation, and industry news, not on providing individualized health guidance.
This content is for informational purposes only and is not medical advice. Consult a qualified healthcare professional for any medical concerns, diagnosis, or treatment.